Biomedical Catalyst: Industry-Led R&D Small Projects (Historical Reference)
Historical reference to Innovate UK’s closed 2025 Biomedical Catalyst industry-led R&D small-projects competition for UK SME health innovation. UKRI and the official briefing give a 10 December 2025 deadline; the archived IFS record shows 11 December. No replacement SME applicant round is listed in the official sources checked as of 2026-10-03.
Biomedical Catalyst: Industry-Led R&D Small Projects (Historical Reference)
Status
Innovate UK’s 2025 Biomedical Catalyst industry-led research and development competition is closed. The official UKRI opportunity page marks the competition closed and identifies UK-registered micro, small and medium-sized enterprises (SMEs) as the intended applicants for health and healthcare innovation projects. The live UKRI opportunity page and the Innovate UK applicant briefing both give 10 December 2025 at 11:00am UK time as the closing date. A cached result for the now-unavailable Innovation Funding Service detail page displayed 11 December 2025, so the archived records conflict; this page uses the date published on UKRI’s live opportunity page and in the briefing. That UKRI date is retained in the deadline field as the historical round’s closing date.
The wider Biomedical Catalyst programme remains part of Innovate UK’s support for health and life-sciences innovation. UKRI’s programme overview describes Accelerator-Feasibility, Industry-led R&D and Investor Partnerships, but a programme description is not an open application round. The official opportunity listings checked for this update show no replacement SME applicant call for industry-led R&D small-project grants. In 2026, Innovate UK published early-stage and late-stage Biomedical Catalyst Accelerator Provider Pool expressions of interest. Both sought organisations to join approved provider pools and deliver accelerator support; neither invited SMEs to apply for industry-led R&D project grants. Those provider-pool calls are also closed. This page is therefore a historical reference, not an invitation to apply. No future deadline should be inferred from the archived timetable.
At a glance
| Item | Closed 2025 competition |
|---|---|
| Programme and funder | Innovate UK Biomedical Catalyst |
| Funding type | Grant |
| Overall competition fund | Up to £25 million, subject to enough high-quality applications |
| Strand covered here | Small projects, with a grant request from £150,000 to £500,000 |
| Maximum total eligible project costs | £1 million |
| Competition status | Closed |
| UKRI opportunity page closing date | 10 December 2025 at 11:00am UK time |
| Official applicant briefing deadline | 10 December 2025 at 11:00am UK time |
| Project duration | 6 to 24 months |
| Project start and end limits | Start by 1 July 2026 and finish by 30 June 2028 |
| Intended applicants | UK-registered micro, small and medium-sized enterprises leading alone or in a collaboration |
All amounts, eligibility rules and process notes below describe that closed competition. They are included to make the record useful for comparison and research, not as current instructions. A later call may set different limits, eligible activities, questions, dates and submission mechanics.
What the competition was designed to support
The 2025 industry-led R&D competition supported pre-market work to develop innovative answers to health and healthcare challenges. Innovate UK described a need for applicants to show existing evidence of commercial and technical feasibility. A proposal also had to explain how the project would improve the competitiveness and productivity of at least one UK SME involved in it. The intention was to advance a defined innovation project, rather than fund an idea without feasibility evidence or routine business activity.
The published scope included disease prevention and proactive management of health conditions; earlier detection and diagnosis; tailored treatments; changes to healthcare delivery; digital health technologies; and consumer-focused self-care. The list was not exhaustive. More specific examples included advanced therapies, bioscience platforms, preclinical tools, therapeutics, diagnostics and biomarkers, medical technologies, precision medicine, data-driven health, and healthy ageing. The breadth of this list did not remove the requirement to explain the health need, technical approach, commercial context and benefit to a UK SME.
The competition excluded fundamental research and feasibility studies, work unrelated to human life sciences, products already on the market, laboratory accreditation, routine business activities without R&D, proposals lacking clear innovation or patient or commercial impact, and projects that failed to meet animal welfare standards. The rules also excluded subsidies dependent on export performance or use of domestic inputs. These scope boundaries formed part of the original competition, and should not be assumed to govern any future Biomedical Catalyst call.
Funding and project limits
This page covers the small-projects strand. Applicants could request between £150,000 and £500,000 in grant funding, and total eligible project costs could be up to £1 million. The separate large-projects strand was for requests above £500,000. Innovate UK said that the two strands were assessed as distinct routes and that an application submitted to the wrong strand would not be transferred for assessment.
The £25 million figure was the overall competition allocation, not a promise that each applicant or the small-projects strand would receive a fixed share. Funding was subject to receipt of a sufficient number of high-quality applications. Grant support did not cover every eligible cost automatically: the balance between eligible costs and the grant awarded had to be funded by the organisation receiving the grant.
The competition applied different maximum grant rates according to organisation size and research category. For industrial research, the published caps were up to 70% for a micro or small organisation, 60% for a medium-sized organisation and 50% for a large organisation. For experimental development, which the guidance described as nearer to market, the corresponding caps were 45%, 35% and 25%. These percentages were ceilings, not guaranteed award rates. A team preparing a historical comparison should read them alongside the cost categories and project rules in the original competition guidance rather than treating them as a simple flat match-funding formula.
A collaborative project required at least two grant-claiming partners. SMEs had to share at least 50% of total project costs, and no single partner could be allocated more than 70% of those costs. The project duration had to be between 6 and 24 months, start by 1 July 2026, and end by 30 June 2028. The briefing set a latest start date; a project could start earlier if the Grant Offer Letter had been approved and its start date met the competition rules. Projects had to start on the first day of a month. Any funded organisation had to carry out its project work in the UK and intend to exploit the results from or in the UK.
Who could apply
A single applicant could apply, as could a collaboration. To apply alone or lead a collaborative application, the lead organisation had to be a UK-registered micro, small or medium-sized enterprise claiming grant funding in the application. An academic institution could not lead or apply alone. Eligible collaborator types in the competition included UK-registered businesses of any size, academic institutions, charities, not-for-profit organisations, public-sector organisations and research and technology organisations (RTOs). The full competition conditions determined each organisation’s costs, grant claim and responsibilities.
The official applicant briefing set application-count limits across both strands: an SME could lead one application and be included as a collaborator in two further applications. If an SME did not lead any application, it could collaborate in any number of applications. A research and technology organisation, large business, academic institution, charity, not-for-profit or public-sector organisation could also collaborate on any number of applications. These limits applied to that competition only and do not establish eligibility for a later call.
The project had to address human health or healthcare and have a credible pre-market R&D plan. Teams also needed to account for permits, licences, sanctions requirements, and animal welfare where relevant. Projects involving animals had to comply with UKRI guidance on animal use in research and innovation; selected projects could be asked for further welfare and ethical information during setup. A collaborator’s presence did not remove the lead SME’s responsibility to ensure the application met the scope and eligibility rules.
How the closed application worked
Applications were submitted through the Innovation Funding Service. The official competition divided the application into four sections: project details, application questions, finances and project impact. This outline records the former workflow only. The original application is closed, and its archived IFS route may not be available for a new submission.
Project details captured the team, title, start date, duration and research category, along with the project summary, public description and scope explanation. The project summary could include up to 10 keywords to help select assessors. The public description had to be suitable for publication and omit commercially sensitive information. The scope answer needed to connect the proposed work to the competition’s stated objectives; out-of-scope applications would not be sent for assessment.
Application questions asked applicants to explain their project against the competition criteria. The detailed guidance set the questions and assessment rubric, so teams needed to consult the competition-specific assessor guidance rather than rely on a generic template. The competition asked applicants not to include website addresses in their answers. The archived page’s assessor guidance and question wording should be checked before drawing conclusions about how a proposal was scored.
Finances required the participating organisations to enter their eligible project costs and grant requests. Applicants needed to check the request against the small-projects band, cost cap, organisation-specific grant rates and collaboration conditions. The lead also needed to ensure that partner figures and the distribution of SME costs were consistent across the application. A grant request inside the published range did not by itself establish that the project budget was eligible or that the maximum rate would be awarded.
Project impact gathered the project-level impact information requested by the service. For a collaborative application, the lead had to invite each partner into IFS. Before submission, the lead was responsible for checking that the information was correct, that the proposal met the scope and eligibility requirements, and that every section was complete. Partners had to complete their assigned sections and accept the terms and conditions. After an initial submission, the lead could reopen the application and had to resubmit it before the competition deadline for changes to count.
The competition guidance recommended contacting Innovate UK at least 15 working days before closing if an applicant needed support or an accessibility adjustment. This was advice for the old deadline, not a current service window. Successful applicants who received a grant offer were directed to complete project setup in IFS. Setup included checks on the organisation and eligible costs and collection of project information, such as bank details. The project could start only after the Grant Offer Letter had been approved.
Historical timeline and assessment
The UKRI opportunity page lists the competition opening as 10 November 2025 at 9:30am UK time and its submission deadline as 10 December 2025 at 11:00am UK time. The applicant briefing gives the same opening and closing dates. Although a cached IFS detail-page result displayed 11 December 2025, that page is no longer available and conflicts with both live UKRI information and the briefing. The briefing says projects had to start by 1 July 2026 and, for the small-projects strand, finish by 30 June 2028. These dates describe a closed competition and do not indicate that funds or application places remain available.
The briefing schedules interviews between 26 March 2026 and 1 April 2026 for large projects only. Small-project applicants were not subject to that interview stage. Applicants were due to be informed by 9 April 2026 at 5:00pm. These milestones are retained as historical context, not as active steps for an application.
The briefing describes independent assessment of the written application. For the small-projects strand, the official record describes review by five independent assessors against the published criteria. A proposal’s technical strength alone did not guarantee an award. Innovate UK could consider its fit, feasibility, team, impact and value, and the competition used a portfolio approach across technologies, themes, strands and research categories.
Using this archive
Use this page to understand the shape of the 2025 small-projects competition, compare historical grant parameters, or identify questions to investigate if Innovate UK publishes another call. Do not use it to decide that a current project is eligible. In particular, do not carry the 2025 request range, SME rules, partner limits, funding rates, dates or application sections into a new application without checking that new competition’s own official guidance.
For current information, check Innovate UK and UKRI’s opportunity listings and read the full competition brief linked from any newly announced call. A future announcement may have a different name, scope or delivery model. UKRI’s 2026 early-stage and late-stage Accelerator Provider Pool opportunities concerned organisations delivering accelerator support; they were not SME grant competitions. No replacement SME industry-led R&D applicant round was announced in the official listings checked for this update. Until Innovate UK publishes one, the 2025 small-projects round remains a closed historical reference.
Official sources
- UKRI opportunity summary: Biomedical Catalyst 2025 industry-led R&D small projects
- Official Innovate UK applicant briefing slides for the Biomedical Catalyst 2025 competition
- UKRI opportunity: Biomedical Catalyst Accelerator Provider Pool, early stage
- UKRI opportunity: Biomedical Catalyst Accelerator Provider Pool, late stage